Latest News & Features
Europe
HGF has promoted Mike Nelson to partner. He joined the firm last year to work with the pharmaceutical and chemistry teams after arriving from AstraZeneca. 1 May 2014
Asia
Patent protection in the pharmaceutical sector in India has raised “serious” concerns, the US government said yesterday, April 30, in its annual Special 301 Report. 1 May 2014
Americas
With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson. 30 April 2014
Asia
International damage may result from India’s steps to formalise its isolationist patents regime, says Jason Rutt. 30 April 2014
Europe
Horizon Discovery’s cell line-creating technology has the potential to advance personalised medicine. But how does the gene editing company stay
competitive in a crowded field? LSIPR found out. 30 April 2014
Asia
Arguments over the term of the patents granted are at the heart of the Copaxone conflict, says Archana Shanker. 30 April 2014
Americas
Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib). 29 April 2014
Americas
AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department. 28 April 2014
Americas
Pfizer’s associate general counsel, Justin McCarthy, has sent a letter to India’s ambassador to the US, Subrahmanyam Jaishankar, urging the Indian government to “shift from using destructive IP policy as an access strategy,” according to reports. 25 April 2014
Americas
The US Court of Appeals for the Federal Circuit has thrown out a lower court ruling that found Natco Pharma infringed a patent covering Roche’s flu drug Tamiflu (oseltamivir phosphate). 25 April 2014